Literature DB >> 26862487

Current treatment options for patients with initially unresectable isolated colorectal liver metastases.

Ozkan Kanat1.   

Abstract

The development of liver metastases is a common clinical entity in the clinical course of colorectal cancer. For patients with isolated liver involvement, surgical resection is the only treatment that can provide a chance of prolonged survival and cure. However, most of these patients are not initially eligible for the surgery. Selected patients with initially considered to have unresectable disease may become resectable after systemic (chemotherapy ± biological therapy) and loco-regional treatment modalities including hepatic arterial infusion. Patients who have colorectal liver metastases ideally should be referred to a multidisciplinary cancer care team in order to identify the most optimal management approach.

Entities:  

Keywords:  Colorectal cancer; Conversion therapy; Hepatic arterial infusion; Liver metastases; Targeted therapy

Year:  2016        PMID: 26862487      PMCID: PMC4734940          DOI: 10.5306/wjco.v7.i1.9

Source DB:  PubMed          Journal:  World J Clin Oncol        ISSN: 2218-4333


  40 in total

Review 1.  Chemotherapy for the conversion of unresectable colorectal cancer liver metastases to resection.

Authors:  Derek G Power; Nancy E Kemeny
Journal:  Crit Rev Oncol Hematol       Date:  2010-10-22       Impact factor: 6.312

Review 2.  Optimal approach to potentially resectable liver metastases from colorectal cancer.

Authors:  Alfredo Falcone; Lorenzo Fornaro; Fotios Loupakis; Gianluca Masi; Enrico Vasile
Journal:  Expert Rev Anticancer Ther       Date:  2008-10       Impact factor: 4.512

3.  Biliary sclerosis after hepatic arterial infusion pump chemotherapy for patients with colorectal cancer liver metastasis: incidence, clinical features, and risk factors.

Authors:  Kaori Ito; Hiromichi Ito; Nancy E Kemeny; Mithat Gonen; Peter J Allen; Philip B Paty; Yuman Fong; Ronald P Dematteo; Leslie H Blumgart; William R Jarnagin; Michael I D'Angelica
Journal:  Ann Surg Oncol       Date:  2011-10-12       Impact factor: 5.344

4.  Technical complications and durability of hepatic artery infusion pumps for unresectable colorectal liver metastases: an institutional experience of 544 consecutive cases.

Authors:  Peter J Allen; Aviram Nissan; Antonio I Picon; Nancy Kemeny; Paul Dudrick; Leah Ben-Porat; Joseph Espat; Alexander Stojadinovic; Alfred M Cohen; Yuman Fong; Philip B Paty
Journal:  J Am Coll Surg       Date:  2005-07       Impact factor: 6.113

5.  Cetuximab plus chronomodulated irinotecan, 5-fluorouracil, leucovorin and oxaliplatin as neoadjuvant chemotherapy in colorectal liver metastases: POCHER trial.

Authors:  C Garufi; A Torsello; S Tumolo; G M Ettorre; M Zeuli; C Campanella; G Vennarecci; M Mottolese; I Sperduti; F Cognetti
Journal:  Br J Cancer       Date:  2010-10-19       Impact factor: 7.640

6.  Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial.

Authors:  Gunnar Folprecht; Thomas Gruenberger; Wolf O Bechstein; Hans-Rudolf Raab; Florian Lordick; Jörg T Hartmann; Hauke Lang; Andrea Frilling; Jan Stoehlmacher; Jürgen Weitz; Ralf Konopke; Christian Stroszczynski; Torsten Liersch; Detlev Ockert; Thomas Herrmann; Eray Goekkurt; Fabio Parisi; Claus-Henning Köhne
Journal:  Lancet Oncol       Date:  2009-11-26       Impact factor: 41.316

7.  Conversion to complete resection and/or ablation using hepatic artery infusional chemotherapy in patients with unresectable liver metastases from colorectal cancer: a decade of experience at a single institution.

Authors:  John B Ammori; Nancy E Kemeny; Yuman Fong; Andrea Cercek; Ronald P Dematteo; Peter J Allen; T Peter Kingham; Mithat Gonen; Philip B Paty; William R Jarnagin; Michael I D'Angelica
Journal:  Ann Surg Oncol       Date:  2013-06-15       Impact factor: 5.344

8.  Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.

Authors:  Leonard B Saltz; Stephen Clarke; Eduardo Díaz-Rubio; Werner Scheithauer; Arie Figer; Ralph Wong; Sheryl Koski; Mikhail Lichinitser; Tsai-Shen Yang; Fernando Rivera; Felix Couture; Florin Sirzén; Jim Cassidy
Journal:  J Clin Oncol       Date:  2008-04-20       Impact factor: 44.544

Review 9.  Management of colorectal cancer presenting with synchronous liver metastases.

Authors:  Ajith K Siriwardena; James M Mason; Saifee Mullamitha; Helen C Hancock; Santhalingam Jegatheeswaran
Journal:  Nat Rev Clin Oncol       Date:  2014-06-03       Impact factor: 66.675

10.  Bevacizumab plus mFOLFOX-6 or FOLFOXIRI in patients with initially unresectable liver metastases from colorectal cancer: the OLIVIA multinational randomised phase II trial.

Authors:  T Gruenberger; J Bridgewater; I Chau; P García Alfonso; M Rivoire; S Mudan; S Lasserre; F Hermann; D Waterkamp; R Adam
Journal:  Ann Oncol       Date:  2014-12-23       Impact factor: 32.976

View more
  4 in total

1.  Neo-adjuvant Chemotherapy-Induced Neutropenia Is Associated with Histological Responses and Outcomes after the Resection of Colorectal Liver Metastases.

Authors:  Qichen Chen; Chaorui Wu; Hong Zhao; Jianxiong Wu; Jianjun Zhao; Xinyu Bi; Zhiyu Li; Zhen Huang; Yefan Zhang; Jianguo Zhou; Jianqiang Cai
Journal:  J Gastrointest Surg       Date:  2019-04-01       Impact factor: 3.452

2.  Laparoscopic vs Open Surgery for Colorectal Liver Metastases.

Authors:  Francesca Ratti; Guido Fiorentini; Federica Cipriani; Marco Catena; Michele Paganelli; Luca Aldrighetti
Journal:  JAMA Surg       Date:  2018-11-01       Impact factor: 14.766

3.  From the completion of neoadjuvant chemotherapy to surgery for colorectal cancer liver metastasis: What is the optimal timing?

Authors:  Qichen Chen; Rui Mao; Jianjun Zhao; Xinyu Bi; Zhiyu Li; Zhen Huang; Yefan Zhang; Jianguo Zhou; Hong Zhao; Jianqiang Cai
Journal:  Cancer Med       Date:  2020-09-04       Impact factor: 4.452

4.  A case report of rectal adenocarcinoma with intrahepatic cholangiocarcinoma of the liver.

Authors:  Jing-Qiang Guo; Jing-Jing Zou; Jin-de Zhu; Chuan Jiang; Chu-Xiao Shao
Journal:  J Int Med Res       Date:  2019-10-03       Impact factor: 1.671

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.